Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

Summary

This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.

Timeline

Start

2018-09-01

Primary completion

2019-05-01

Completion

2019-12-31

Publications

• Lommatzsch M, Marchewski H, Schwefel G, Stoll P, Virchow JC, Bratke K. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin Exp Allergy. 2020 Nov;50(11):1267-1269. doi: 10.1111/cea.13720. Epub 2020 Aug 26. No abstract available.

Drugs

Indications